20:09 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Sage raises $575M in follow-on

Weeks ahead of the PDUFA date for its antidepressant Zulresso brexanolone, Sage Therapeutics Inc. (NASDAQ:SAGE) raised $575 million in a follow-on. Including an overallotment priced Wednesday, the company sold 3.8 million shares at $150, a...
19:06 , Dec 14, 2018 |  BC Week In Review  |  Financial News

Momenta, Global Blood price follow-ons

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Global Blood Therapeutics Inc. (NASDAQ:GBT) each priced follow-ons, raising a total of $350 million. Momenta raised $200 million Dec. 6 through the sale of 17.4 million shares at $11.50. The...
01:19 , Oct 6, 2018 |  BioCentury  |  Finance

In sight of uncharted territory

Strong growth from small- and mid-caps coupled with a late run from large cap biotechs has pushed the sector within sight of its all-time high in 2015. Some buysiders now are seeing red flags of...
21:44 , Jul 10, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Other An encapsulated, ionic solvent-based formulation of insulin could enable longer-lasting treatment of Type I diabetes than injected insulin. The formulation consists oral, enterically coated capsules containing insulin dispersed in a deep eutectic solvent...
12:05 , May 3, 2018 |  BioCentury  |  Finance

Foresite into data

With a new $668 million fund, Foresite Capital is positioning itself to invest in more healthcare companies that use data science and machine learning in drug discovery and development, diagnostics, and patient identification and monitoring....
19:58 , Apr 27, 2018 |  BC Week In Review  |  Financial News

10x Genomics raises $125M in series D, credit facility

10x Genomics Inc. (Pleasanton, Calif.) raised $50 million on April 26 in an untranched series D round led by new investor Meritech Capital Partners. New investor Wells Fargo Strategic Capital also participated, as did existing...
18:36 , Apr 26, 2018 |  BC Extra  |  Financial News

10x Genomics raises $125M in series D, credit facility

10x Genomics Inc. (Pleasanton, Calif.) raised $50 million in an untranched series D round led by new investor Meritech Capital Partners. New investor Wells Fargo Strategic Capital also participated, as did existing investors Paladin Capital,...
21:12 , Mar 2, 2018 |  BioCentury  |  Finance

Genome toolbox

The syndicate behind Inscripta Inc.’s $55.5 million series C round includes investors well-versed in genome reading and writing that are making a foray into genome editing. New investor Mérieux Développement and existing investor Paladin Capital...
00:38 , Mar 23, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens; drug platforms

TECHNOLOGY: Cellular assays; peptides A genomic and proteomic screening method could identify neoantigens as personalized immunotherapy targets for cancer. The method involved collecting tumor and non-tumor tissue samples from a patient; immunoprecipitating human leukocyte antigen...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

10x Genomics sales and marketing update

10x launched the Chromium Single Cell Controller for single-cell analytics in the U.S. for $50,000. The company did not respond to inquiries. 10x Genomics Inc. , Pleasanton, Calif.  Business: Genomics ...